1 / 40

CoreValve US Pivotal Trial High-Risk Arm

CoreValve US Pivotal Trial High-Risk Arm. Device and Access Routes. End Points. Patient Eligibility a. Study Disposition. Baseline Demographics. Results 1 Year All-Cause Mortality. Results Noninferiority and Superiority. Results 2-Year All-cause Mortality (Preliminary Results).

thaddeus-lowery
Télécharger la présentation

CoreValve US Pivotal Trial High-Risk Arm

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CoreValve US Pivotal TrialHigh-Risk Arm

  2. Device and Access Routes

  3. End Points

  4. Patient Eligibilitya

  5. Study Disposition

  6. Baseline Demographics

  7. Results 1 Year All-Cause Mortality

  8. Results Noninferiority and Superiority

  9. Results 2-Year All-cause Mortality (Preliminary Results)

  10. Clinical Patient Outcomes

  11. Results All Stroke

  12. Secondary End Points

  13. 1-Year MACCE

  14. Other End Points

  15. Paravalvular Regurgitation

  16. Subgroup Analysis1 Year

  17. Subgroup Analysis1 Year (cont)

  18. Conclusion

  19. CoreValve US Pivotal Trial In Context

  20. What Did We Learn?

  21. Surgical Outcomes

  22. Patient SelectionWhat Is High Risk?

  23. Key Inclusion Criteria

  24. Study Population – In Context

  25. Expanded Patient Population

  26. Loss to Follow-Up: Sensitivity Analyses

  27. Future TAVR vs SAVR Trial Design Considerations

  28. TAVR in Community Practice

  29. The TVT Registry

  30. TVT 1-Year Outcomesa

  31. TAVR Device Comparison Trials

  32. CHOICE Key Outcomes

  33. CHOICEClinical Implications

  34. TAVR in Clinical Practice: Moving Forward

  35. Abbreviations

  36. Abbreviations (cont)

  37. References

  38. References (cont)

More Related